Surgical options in undifferentiated thyroid carcinoma

World Journal of Surgery

Volumn 31, Issue 5, 2007, Pages 969-977

  Lang, Brian Hung Hin ^a   Lo, Chung Yau ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; COMBRETASTATIN A4; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN P53; RIBONUCLEASE INHIBITOR; SODIUM IODIDE SYMPORTER; VASCULOTROPIN INHIBITOR; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; HUMAN; LYMPH NODE DISSECTION; MORBIDITY; NONHUMAN; PROGNOSIS; THYROID CARCINOMA; TRACHEOSTOMY; TREATMENT INDICATION; TUMOR DIFFERENTIATION;

CARCINOMA; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; NECK DISSECTION; NEOPLASM METASTASIS; PALLIATIVE CARE; PROGNOSIS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 34248203755     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-007-0776-7     Document Type: Article

References (59)

1. Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing?. Ann Surg Oncol 2004;11:(12) 1093-1097.
2. Reynolds RM, Weir J, Stockton DL, et al. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf) 2005;62:156-162.
3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-2167.
4. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006;13:119-128.
5. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-464.
6. Ain KB. Anaplastic thyroid carcinoma: behaviour, biology, and therapeutic approaches. Thyroid 1998;8:715-716.
7. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 1999;16:64-69.
8. Rosai J, Saxen EA, Woolner L. Undifferentiated and poorly differentiated carcinoma. Semin Diagn Pathol 198;5:2-123-136.
9. Auersperg M, Us-Krasovec M, Petric G, et al. Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma. Wien Klin Wochenschr 1990;102:267-270.
10. Venkatesh S, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer 1990;66:321-330.
11. Schlumberger M, Parmentier C, Delisle MJ, et al. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991;67:564-566.
12. Wong CS, Van Dyk J, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1991;20:3-9.
13. DeMeter JG, De Jong SA, Lawrence AM, et al. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 2001;110:956-961.
14. Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992;18:83-88.
15. Hadar T, Mor C, Shvero J, et al. Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 1993;19:511-516.
16. Levendag PC, De Porre PM, van Putten WL. Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 1993;26:125-128.
17. Tennvall J, Lundell G, Hallquist A, et al. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. The Swedish Anaplastic Thyroid Cancer Group. Cancer 1994;74:1348-1354.
18. Biganzoli L, Gebbia V, Maiorino L, et al. Thyroid cancer: different outcomes to chemotherapy according to tumour histology. Eur J Cancer 1995;31:2423-2424.
19. Tan RK, Finley RK 3rd, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17:71-77.
20. Kobayashi T, Asakawa H, Umeshita K, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996;18:36-41.
21. Nilsson O, Lindeberg J, Zedenius J, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 1998;22:725-730.
22. Lo CY, Lam KY, Wan KY. Anaplastic carcinoma of thyroid. Am J Surg 1999;177:337-339.
23. Passler C, Scheuba C, Prager G, et al. Anaplastic (undifferentiated) thyroid carcinoma (ATC): a retrospective analysis. Langenbeck's Arch Surg 1999;384:284-293.
24. Voutilainen PE, Multanen M, Haapiainen RK, et al. Anaplastic thyroid carcinoma survival. World J Surg 1999;23:975-979.
25. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninetysix-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10:587-94.
26. Lam KY, Lo CY, Chan KW, et al. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg 2000;231:329-38.
27. Rodriguez JM, Pinero A, Ortiz S, et al. Clinical and histological differences in anaplastic thyroid carcinoma. Eur J Surg 2000;166:34-38.
28. Busnardo B, Daniele O, Pelizzo MR, et al. A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Invest 2000;23:755-761.
29. Haigh PI, Ituarte PHG, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335-2342.
30. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-1034.
31. Besic N, Auersperg M, Us-Krasovec M, et al. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 2001;27:260-264.
32. Sugitani I, Kasai N, Fujimoto Y, et al. Prognostic factors and therapeutic strategy for naplastic carcinoma of the thyroid. World J Surg 2001;25:617-622.
33. Pierie JP, Muzikansky A, Gaz RD, et al. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002;9:57-62.
34. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractiontated radiotherapy and surgery. Br J Cancer 2002;86:1848-1853.
35. Sugino K, Ito K, Mimura T, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002;131:245-248.
36. De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractiontated accelerated external radiotherapy. Int J Radiation Oncology Biol Phys 2004;60:1137-1143.
37. Kihara M, Miyauchi A, Yamauchi A, et al. Prognostic factors in anaplastic thyroid carcinoma. Surg Today 2004;34:394-398.
38. Veness MJ, Porter GS, Morgan GJ. Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ J Surg 2004;74:559-562.
39. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma: treatment outcomes and prognostic factors. Cancer 2005;103:1330-1335.
40. Goutsouliak V, Hay JH. Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol (R Coll Radiol) 2005;17:75-78.
41. Besic N, Hocevar M, Zgajnar J, et al. Prognostic factors in anaplastic carcinoma of the thyroid - a multivariate analysis of 188 patients. Langenbecks Arch Surg 2005;390:203-208.
42. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989;95S:2-4.
43. Heinrich S, Schä fer M, Rousson V, et al. Evidence-based treatment of acute pancreatitis. A look at established paradigms. Ann Surg 2006;243:154-168.
44. Greene FL, Page DL, Fleming ID, et al. (2002) AJCC Cancer Staging Handbook: TNM classification of malignant tumors, Sixth Edition Springer-Verlag, New York, .
45. Thyroid Carcinoma Task ForceAACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001;7:202-220.
46. Hermann M, Kober F, Hollinsky C, et al. Reinterventions in anaplastic cancers and sarcomas of the thyroid gland. Wien Klin Wochenshr 1990;102:260-264.
47. Holting T, Meybier H, Buhr H. Status of tracheotomy in treatment of the respiratory emergency in anaplastic thyroid cancer. Wien Klin Wochenschr 1990;102:264-266.
48. Hunt JL, Tometsko M, LiVolsi VA, et al. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003;27:1559-564.
49. Moretti F, Farsetti A, Soddu S, et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997; 14:729-740.
50. Fagin JA, Tang SH, Zeki K, et al. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 1996;56:765-771.
51. Blagosklonny MV, Giannakakou P, Wojtowicz M, et al. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cells. J Clin Endocrinol Metab 1998;83:2516-2522.
52. Nagayama Y, Yokoi H, Takeda K, et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 2000;85:4081-4086.
53. Copland JA, Marlow LA, Kurakata S, et al. Novel highaffinity PPARc agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/C1P1. Oncogene 2006;25:2034-2017.
54. Smit JW, der Shroder-van Elst JP, et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 2000;10:939-943.
55. She M, Yeung SCJ. Combining a matrix metalloproteinase inhibitor, a farnseyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model. Cancer Letters 2006;238:197-201.
56. Kim S, Schiff BA, Yigitbasi OG, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE 788. Mol Cancer Ther 2006;4:632-640.
57. Shi Y, Zou M, Collison K, et al. Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 2006;91:2373-2379.
58. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Research 2004;10:8594-8602.
59. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-2189.